Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dipyrone + codeine
- Development stage
- Phase 3
- Lead developer
- Eurofarma
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Oral
01
Overview
Dipyrone (also known as metamizole) combined with codeine is a fixed-dose combination analgesic developed for the treatment of moderate to severe pain, particularly postoperative pain. Dipyrone is a non-opioid analgesic and antipyretic with additional spasmolytic properties. Its mechanism of action involves inhibition of cyclooxygenase enzymes COX-1 and COX-2, leading to reduced prostaglandin synthesis; it may also activate the opioidergic, cannabinoid, and endovanilloid systems. Codeine is an opioid analgesic that acts primarily as a mu-opioid receptor agonist to provide pain relief. The combination aims to enhance analgesia through complementary mechanisms while potentially reducing opioid requirements. Dipyrone/codeine combinations are marketed in some countries but not available in others due to safety concerns regarding dipyrone (notably agranulocytosis). Eurofarma has been identified as a developer for this fixed-dose combination[3][5][1].
- Other names
- metamizole + codeinemetamizol + codeine
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on dipyrone + codeine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dipyrone + codeine.